Guest_Joe_*
12-12-2004, 01:53 PM
At the SABCS meetings in San Antonio, we met with representatives of Allos Pharmaceuticals to discuss their current clinical trials of Efaproxiral (RSR13).
This drug is a small molecule that binds to hemogloben to facilitate oxygen unloading from hemogloben to hypoxic tumor tissue prior to radiation therapy. The result is an improvement in the effectiveness of the whole brain radiation.
This drug was originally turned down by the FDA for approval because it did not prove to have any overall benefit to all types of brain tumors, EXCEPT WOMEN WITH BRAIN METASTASES FROM BREAST CANCER !!
The data showed that this sub-group experienced significant improvement.
As a result of these findings the FDA has approved clinical trials for this group and has fast tracked the drug for early approval.
This is a blind but open label clinical trial, which means that not all women will receive the drug, but you will know from the onset if you do. If you were chosen not to reciene the drug you will be placed in the control group and also be clinicaly followed.
We highly recommend that if you are scheduled to undergo whole brain radiation, that you enroll in this trial. Not only will this benefit you, but may help other women in the future.
Allos Efaproxiral Clinical Study (http://www.allos.com/index.cfm?p2=96190120&category1=clin&category2=enri&category3=x&category4=x&category5=x&category6=x)
Warmest Regards
Joe
This drug is a small molecule that binds to hemogloben to facilitate oxygen unloading from hemogloben to hypoxic tumor tissue prior to radiation therapy. The result is an improvement in the effectiveness of the whole brain radiation.
This drug was originally turned down by the FDA for approval because it did not prove to have any overall benefit to all types of brain tumors, EXCEPT WOMEN WITH BRAIN METASTASES FROM BREAST CANCER !!
The data showed that this sub-group experienced significant improvement.
As a result of these findings the FDA has approved clinical trials for this group and has fast tracked the drug for early approval.
This is a blind but open label clinical trial, which means that not all women will receive the drug, but you will know from the onset if you do. If you were chosen not to reciene the drug you will be placed in the control group and also be clinicaly followed.
We highly recommend that if you are scheduled to undergo whole brain radiation, that you enroll in this trial. Not only will this benefit you, but may help other women in the future.
Allos Efaproxiral Clinical Study (http://www.allos.com/index.cfm?p2=96190120&category1=clin&category2=enri&category3=x&category4=x&category5=x&category6=x)
Warmest Regards
Joe